Alnylam Pharma (ALNY) Misses Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Alnylam Pharmaceuticals (ALNY) PT Lowered to $175 at BMO Capital
February 11, 2022 7:21 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $175.00 (from $180.00) while maintaining a Market Perform rating.
The analyst commented, "Solid 4Q product revenue was preannounced as key commercial products (Onpattro/Givlaari/Oxlumo) continue good momentum with increased... More
